Cardiovascular diseases (CVDs) are common in patients with Non-insulin-dependent diabetes mellitus (NIDDM). Lack of exercise and obesity in the population; the main causes of T2D prevalence. Therefore there is a need for joint treatment of diabetes and CVDs. Calcium-channel-blocking drugs and angiotensin-converting–enzyme (ACE) inhibitors are considered very effective. Angiotensin-converting–enzyme (ACE) inhibitors are thought to be very efficient in reducing the risk of death and hospitalization in patients with HF (heart failure). These inhibitors act as potential regulators of insulin and cardiac failure. This review article focused on the mechanism of action of two the action of drugs, Enalapril (angiotensin-converting–enzyme (ACE) inhibitors) and nifedipine (Calcium-channel-blocker), and their clinical effect on reducing the CVDs and heart failure in T2DM patients. Furthermore, novel immuno targets are needed to discover in future that may lower the risk of deaths among diabetes patients.